Carol_Meschter Blog


The (Non)Reproducibility Crisis, Part 2

By On August 2, 2017

In Part 1 of this series, we gave a general introduction to the problem of non-reproducibility of preclinical studies and some reasons why CROs including Comparative Biosciences are somewhat immune to it.… Read More


The (Non)Reproducibility Crisis, Part 1

By On July 25, 2017

John Ioannidis’s 2005 paper, “Why most published research findings are false”[1] set off a cascade of discussion, despite its impenetrability, not least because of its sensational title.  Concerns about non-reproducibility have been… Read More


Laser-induced Choroidal Neovascularization in the Mini Pig

By On May 23, 2017

A validated model for posterior segment proliferative ocular disease at CBI CBI is known throughout the Industry as a premier ocular preclinical CRO.  For over 10 years, we have offered established in-house… Read More


Thermal and UV Burn Modeling at CBI

By On March 24, 2017

Thermal and UV burns represent an unmet medical need, particularly in defense or military settings.  CBI has a number of humane, validated and optimized superficial, partial thickness and full thickness burn models… Read More


Rabbit Hypertrophic Scar or Keloid Model

By On March 23, 2017

At CBI we offer the Rabbit Hypertrophic Scar or Keloid Model.  This is a validated and established model that assessed the effects of various test articles on scar formation or resolution.  In… Read More


New Capabilities: Histology, Immunohistochemistry and Histomorphometry at CBI

By On March 15, 2017

The CBI histology laboratory is offering some new capabilities!  In addition to our standard histology, pathology, immunohistochemistry and histomorphometry in both a research and GLP environment, we have just presented a poster… Read More


Postnatal Hyperoxia-induced Lung Injury at CBI

By On March 14, 2017

Neonatal hyper-oxygenation has been demonstrated to produce bronchopulmonary dysplasia. Developing treatments for this syndrome is an unmet medical need. Here at CBI, we have developed and validated robust models for this syndrome, for the… Read More


Cancer Immunotherapy-Preclinical Toxicology

By On February 28, 2017

Cancer immunotherapy represents a new and promising area of treatment of cancer.  This is an exciting field and is overseen by the FDA CBER OCTGT division.  A number of new drugs have… Read More


Preclinical Otic Studies at CBI

By On February 23, 2017

We have been offering a variety of otic studies to support test article efficacy, toxicity and pharmacokinetics, particularly to support regulatory submissions, CBI is one of the few CROs which provide specialized… Read More


Cutting Edge Preclinical Infection Modeling

By On February 17, 2017

We have been doing some fascinating and cutting edge anti-infective work.  Not only are we conducting our standard workhorse models, such as Mouse Protection Test and Neutropenic Thigh, but we have been… Read More